Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Atomo Diagnostics Ltd. ( (AU:AT1) ) has provided an announcement.
Atomo Diagnostics reported a modest 6% rise in revenues from ordinary activities to AUD2.18 million for the half year to 31 December 2025, while significantly narrowing its loss. The loss from ordinary activities after tax fell 36% to AUD1.76 million, and the loss for the half-year declined 38% to AUD1.65 million, reflecting improved cost control and operating efficiency.
Basic and diluted earnings per share improved to a loss of 0.22 cents from 0.43 cents a year earlier, highlighting progress toward breakeven despite remaining in the red. Net tangible assets per share slipped to 0.64 cents from 0.72 cents, partly due to an increased share count to 810.2 million, and the company again did not declare a dividend, underscoring its continued focus on reinvestment and capital preservation.
The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited is a medical diagnostics company focused on developing and supplying rapid test solutions. The group operates in point-of-care testing, providing devices designed to deliver quick, user-friendly diagnostic results for healthcare and related markets.
Average Trading Volume: 1,518,283
Technical Sentiment Signal: Buy
Current Market Cap: A$30.79M
Learn more about AT1 stock on TipRanks’ Stock Analysis page.